|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
CHEMICON International, Inc. (SERO) Licenses Quantum Dot Antibody Reagent Line From Quantum Dot Corporation
10/19/2005 5:12:56 PM
ATLANTA & HAYWARD, Calif.--(BUSINESS WIRE)--March 4, 2005--Chemicon International, a subsidiary of Serologicals Corporation (NASDAQ: SERO), and Quantum Dot Corporation (QDC) today announced the signing of an agreement granting Chemicon rights to market specific quantum dot-containing products for the detection of antibody-antigen interactions in immunological experiments. This agreement will add novel secondary antibody detection technologies to Chemicon's general reagents product portfolio. Researchers will be able to use these products for the study of antigen presence in a variety of tissue and cell culture samples. Chemicon is recognized as a worldwide leader in providing specific antibodies, kits and ancillary reagents for the detection of antigen targets in the neuroscience, stem cell, cancer, in vitro diagnostics, and other fields. Chemicon will offer these products through its direct sales team in North America, Australia, UK and much of Europe, as well as through its worldwide network of distributors.
|
|
|
|
|
|
|
|
|
|
|